Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by amorakon Jun 02, 2010 1:31am
574 Views
Post# 17149210

RE: problem...???

RE: problem...???Each drawdown cannot be larger than $500,000 so RVX can only raise about $1 million or so per month unless YA agrees to increasing a draw down amount. A minimum share price can be set for each draw down. For this one it's $4. The minimum protects YA from being forced to buy shares if RVX collapses altogether. However, YA can buy below the minimum if it chooses. That's my understanding from Article 8.1.e. You can find it on SEDA. The maximum number of shares issued under the drawdown could exceed 263,158 if YA decides to buy below the minimum price. So each month, RVX cannot raise through the SEDA enough to match the burn rate. I imagine that's why they're starting early. I don't expect early results from the ASSERT trial. They know how much work they have to do. It's easily predicted.
Bullboard Posts